Led · Series C · Jul 2021

MicroPort CRM is a subsidiary of MicroPort Scientific that designs, develops, manufactures, and markets implantable pacemakers, implantable cardioverter‑defibrillators, cardiac resynchronization systems and ECG diagnostic solutions. Headquartered in Clamart, France, it has R&D teams in Clamart and Shanghai and manufacturing facilities in France, Italy, the Dominican Republic, and China. The company employs approximately 1,100 people and has implanted more than two million patients worldwide with its pacemakers and defibrillators. Recent product launches include the 2015 PLATINIUM family of ICDs, the 2019 ENO/TEO/OTO smallest pacemakers, and 2021 ALIZEA and BOREA pacemakers featuring Bluetooth technology and wireless remote monitoring. Its pipeline includes a new line of 1.5T and 3T MRI‑conditional defibrillator systems, a sub‑cutaneous ICD (S‑ICD), a leadless pacemaker, and the Axone project for delivery of cardiac resynchronization therapy, which the company expects will drive future growth. MicroPort CRM markets globally and will remain majority‑owned by MicroPort following the Series C financing. MicroPort CRM develops and commercializes implantable pacemakers, defibrillators, CRT solutions and related technologies for managing cardiac rhythm disorders. The company has implanted more than one million patients worldwide and employs approximately 950 people globally. It maintains R&D teams in Clamart (outside Paris) and Shanghai and manufacturing facilities in France, Italy, the Dominican Republic and China. Recent and upcoming product plans include the ALIZEA and BOREA pacemaker families with Bluetooth wireless remote monitoring and a new line of defibrillator systems planned for 2021, including 1.5T and 3T MRI-conditional devices and leads. The company is known for small, long-lasting devices (e.g., the PLATINIUM family and world’s smallest pacemakers ENO/TEO/OTO) and innovations in CRT such as the SonR sensor and the AXONE ultra-thin left ventricular lead. The Series B financing and stated valuation reflect investor confidence and are intended to support product introductions and growth of the CRM franchise.

Led · Series D · May 2021

Rapid Medical develops responsive, adjustable neurovascular devices for endovascular diseases, with a focus on minimally invasive treatment of ischemic and hemorrhagic stroke. The company’s flagship TIGERTRIEVER revascularization device received FDA clearance for treatment of ischemic stroke. TIGERTRIEVER 13 is CE marked and is the smallest device in the portfolio, indicated for removal of clots from more distal areas of the brain; TIGERTRIEVER 13 is not FDA cleared. TIGERTRIEVER 17 and 21, COMANECI and COLUMBUS/DRIVEWIRE are CE marked and FDA cleared. Rapid Medical uses a proprietary braiding technology platform and plans to expand commercial operations in the US and Europe, generate additional clinical evidence, advance its product pipeline, and pursue regulatory approvals in strategic territories such as China. Rapid Medical develops interventional neurovascular devices for endovascular treatments and is led by CEO and co-founder Ronen Eckhouse. The company makes TIGERTRIEVER, a controllable, fully visible stentriever for ischemic stroke, and COMANECI, a controllable aneurysm neck-bridging device. Both TIGERTRIEVER and COMANECI are CE marked for use in Europe. Rapid Medical intends to use the Series C proceeds to develop a U.S. commercial presence ahead of regulatory approvals, expand sales and marketing in Europe, and develop additional products. It will also support completion of the TIGER IDE study in the U.S., which has been enrolling patients since May 2018. The company has entered a partnership granting MicroPort marketing rights for TIGERTRIEVER and COMANECI in China. Rapid Medical, led by Dr. Shimon Eckhouse, develops neurovascular interventional devices including TIGERTRIEVER and COMANECI. TIGERTRIEVER is a visible and controllable stentriever designed to treat ischemic stroke, while COMANECI is an aneurysm collar bridging device. Both devices are CE marked and have been used in neurovascular procedures for thousands of patients in Europe. The company closed a $9M Series B financing round to support regulatory and commercial efforts. Rapid Medical intends to use the funds to facilitate U.S. regulatory approvals and to pursue marketing of the two devices in the European market. As part of the financing, investor representatives will join the company's board.

Led · Series C · Apr 2020

Robocath, founded in 2009, designs, develops and commercializes robotic solutions to treat cardiovascular diseases. Its first robotic-assisted platform, R-One™, optimizes safety in coronary angioplasty and is compatible with market-leading devices and cath labs; it is currently available in Europe and Africa. The company is developing a second-generation robot to cover more PCI procedures and to begin peripheral and neurovascular applications. The €40m Series C financing will be used to expand sales and marketing for R-One™ and accelerate product development of the next-generation system. Robocath plans to enter the Asian market through a China-based joint venture with MicroPort that will include local manufacturing, consumable production and robot assembly. Both companies will also pursue R&D on long-distance 5G remote-control technologies and AI algorithms for robotic-assisted platforms. Robocath has more than 30 employees and is backed by investors including GO CAPITAL, NCI, Normandie Participations, M Capital, Supernova Invest, Caisse d’épargne, BNP Paribas, Crédit Agricole and Bpifrance. Robocath develops robotic systems for the treatment of cardiovascular diseases, with a focus on robotic-assisted coronary procedures. Its first product, R-One™, is designed to optimize the safety of robotic-assisted coronary angioplasty. R-One™ received CE marking in February 2019. The company intends to use new funding to roll out its robotic platform in strategic European target markets. Robocath was founded in 2009 and is based in Rouen, France. It is led by newly hired CEO Lucien Goffart alongside founder and president Philippe Bencteux. Robocath develops R-One™, a robotic platform that optimizes and increases the safety of robotic-assisted coronary angioplasty by enabling precise operation from a seated position and using a portable X-ray protective screen. The company plans to market its first robotic platform in Europe and the Middle East in 2018 and will use new funding to increase resources for marketing R-One. Robocath will also launch development of a next-generation robotic platform targeted at neurovascular diseases such as strokes. The company received an additional €1.7M in funding which supplements a €4.7M close in May. Founded in 2009 by Philippe Bencteux, Robocath employs close to 20 staff. The funds are explicitly earmarked for commercialization of R-One and R&D on the next-generation stroke treatment robotics. Robocath designs and develops robotic solutions for the treatment of cardiovascular diseases, with its first platform, the R-one™, aimed at interventional cardiology. The integrated R-one platform is covered by 20 families of international patents and allows physicians to remotely manage instruments from a control panel close to the operating table. R-one incorporates two core technologies—R-grasp®, which reproduces hand movements including rotation and simultaneous movement, and SecurAccess®, which provides stability and security during procedures. The company is currently at the manufacturing stage and is in the process of obtaining the CE mark. Robocath intends to use the new funds for continued development and employs around 20 staff. Founded in 2009 in Rouen, France, the company previously raised €1.8m in 2013 and 2015 and received about €1.6m in public aid from Bpifrance and others.

Led · Series A · Apr 2018

Promaxo is an Oakland, CA–based company that develops portable low-field MRI systems and minimally invasive robotics aimed at improving medical imaging and interventions. Its open, compact MRI has a limited fringe field so it can be placed in clinics or operating rooms and is designed to be compatible with robotic procedures. The Promaxo system enables earlier diagnosis and treatment in a wider range of healthcare settings and is the first in the U.S. to receive FDA 510(k) clearance for prostate biopsy and treatment. Led by Founder and CEO Dr. Amit Vohra, the company is building a minimally invasive, patient-centric MRI and robotic platform that incorporates imaging, robotics and AI capabilities. Promaxo is currently working to obtain FDA clearance for its own robot to further enhance precision and predictability in prostate interventions. Promaxo develops a minimally-invasive, patient-centric MRI and robotic platform for point-of-care diagnostic biopsies and cancer treatment. The company, based in Oakland, California, holds over 200 patents and emphasizes state-of-the-art medical imaging, robotics, and AI capabilities. Promaxo is commercializing a compact and adaptable MRI system and has formed numerous long-term and strategic partnerships with investor groups and corporations. To support continued commercialization and sales, Promaxo announced an upsized asset financing agreement with kineo finance that increases its direct leasing solution. The expanded agreement is intended to support the company’s commercial and customer sales programs and to cover its expected sales pipeline in 2023. Kineo finance is a Swiss-headquartered asset financing group with subsidiaries in the USA and Germany that provides venture leasing and working capital solutions and is backed by institutional investors. Promaxo develops a compact, adaptable MRI and robotic platform intended to enable safe, effective point-of-care diagnostic biopsies and to facilitate cancer treatment through an open architecture. The company emphasizes a minimally-invasive, patient-centric approach and integrates imaging, robotics and AI capabilities. Promaxo says its system overcomes limitations of traditional MRI systems and has received favorable physician feedback. Management highlights a large addressable market, citing a $3 billion market for prostate cancer. The company is based in Oakland, California, was founded by entrepreneurs and healthcare innovators, and is backed by over 200 patents. Promaxo has formed numerous long-term and strategic partnerships as it drives commercialization of its in-office MRI system. Promaxo develops a minimally‑invasive, patient‑centric MRI and robotic platform that combines medical imaging, robotics and AI for point‑of‑care diagnostic biopsies and cancer interventions. The company offers a compact, adaptable MRI system intended to improve the quality and speed of patient diagnosis and procedures. Promaxo is backed by over 90 patents and has formed numerous long‑term and strategic partnerships with investor groups and corporations as it prepares to enter the US market. Management says the platform targets in‑office diagnostic and therapeutic procedures, including a cited $3 billion addressable market for in‑office urology procedures. To expand commercial adoption, Promaxo is adding direct leasing and sales‑and‑lease‑back options for physician practices and academic centers. An asset financing agreement with kineo finance is intended to support these growth initiatives and broaden market penetration of its platform technology. Promaxo develops a minimally-invasive, patient-centric MRI and robotic platform centered on a compact and adaptable MRI system. The company emphasizes incorporation of artificial intelligence into imaging and image-based interventions and holds over 60 patents. Promaxo says its technology aims to improve the quality and speed of patient screening and interventions and to redefine the standard of care. The firm plans to use recent funding to accelerate its data strategy and further integrate AI capabilities. Promaxo has formed numerous long-term and strategic partnerships as it prepares to enter the U.S. market and is based in Oakland, California. Leadership describes a goal of introducing a truly open MRI system to the masses and expanding the frontiers of medical imaging, robotics, and AI.